• 2023
  Blaise O, Leseigneur C, Cokelaer T, Capuzzo E, Frescaline N, Dussurget O, , Complete Genome Sequences of Bioluminescent Staphylococcus aureus Strains Xen31 and Xen36, Derived from Two Clinical Isolates., Microbiol Resour Announc 2023 Feb; (): e0002423.
• 2022
  Dufour-Gaume F, Frescaline N, Cardona V, Prat NJ, , Danger signals in traumatic hemorrhagic shock and new lines for clinical applications., Front Physiol 2022 ; 13(): 999011.
• 2021
  Duchesne C, Frescaline N, Blaise O, Lataillade JJ, Banzet S, Dussurget O, Rousseau A, , Cold Atmospheric Plasma Promotes Killing of Staphylococcus aureus by Macrophages., mSphere 2021 Jun; 6(3): e0021721.
• 2020
  Frescaline N, Duchesne C, Favier M, Onifarasoaniaina R, Guilbert T, Uzan G, Banzet S, Rousseau A, Lataillade JJ, , Physical plasma therapy accelerates wound re-epithelialisation and enhances extracellular matrix formation in cutaneous skin grafts., J Pathol 2020 12; 252(4): 451-464.
• 2020
  Blaise O, Duchesne C, Banzet S, Rousseau A, Frescaline N, , A Murine Model of a Burn Wound Reconstructed with an Allogeneic Skin Graft., J Vis Exp 2020 08; (162): .
• 2019
  Duchesne C, Banzet S, Lataillade JJ, Rousseau A, Frescaline N, , Cold atmospheric plasma modulates endothelial nitric oxide synthase signalling and enhances burn wound neovascularisation., J Pathol 2019 11; 249(3): 368-380.
• 2018
  Peltzer J, Aletti M, Frescaline N, Busson E, Lataillade JJ, Martinaud C, , Mesenchymal Stromal Cells Based Therapy in Systemic Sclerosis: Rational and Challenges., Front Immunol 2018 ; 9(): 2013.
• 2016
  Ruzehaji N, Frantz C, Ponsoye M, Avouac J, Pezet S, Guilbert T, Luccarini JM, Broqua P, Junien JL, Allanore Y, , Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis., Ann Rheum Dis 2016 Dec; 75(12): 2175-2183.
• 2016
  Ponsoye M, Frantz C, Ruzehaji N, Nicco C, Elhai M, Ruiz B, Cauvet A, Pezet S, Brandely ML, Batteux F, Allanore Y, Avouac J, , Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis., Ann Rheum Dis 2016 Dec; 75(12): 2142-2149.
• 2016
  Elhai M, Avouac J, Hoffmann-Vold AM, Ruzehaji N, Amiar O, Ruiz B, Brahiti H, Ponsoye M, Fréchet M, Burgevin A, Pezet S, Sadoine J, Guilbert T, Nicco C, Akiba H, Heissmeyer V, Subramaniam A, Resnick R, Molberg Ø, Kahan A, Chiocchia G, Allanore Y, , OX40L blockade protects against inflammation-driven fibrosis., Proc Natl Acad Sci U S A 2016 07; 113(27): E3901-10.
• 2015
  Ruzehaji N, Avouac J, Elhai M, Frechet M, Frantz C, Ruiz B, Distler JH, Allanore Y, , Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosis., Arthritis Res Ther 2015 May; 17(): 145.
• 2015
  Arismendi M, Giraud M, Ruzehaji N, Dieudé P, Koumakis E, Ruiz B, Airo P, Cusi D, Matucci-Cerinic M, Salvi E, Cuomo G, Hachulla E, Diot E, Caramaschi P, Riccieri V, Avouac J, Kayser C, Allanore Y, , Identification of NF-κB and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis., Arthritis Res Ther 2015 Mar; 17(): 71.
• 2015
  Desterke C, Martinaud C, Ruzehaji N, Le Bousse-Kerdilès MC, , Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis., Mediators Inflamm 2015 ; 2015(): 415024.
• 2014
  Avouac J, Palumbo-Zerr K, Ruzehaji N, Tomcik M, Zerr P, Dees C, Distler A, Beyer C, Schneider H, Distler O, Schett G, Allanore Y, Distler JH, , The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis., Arthritis Rheumatol 2014 Nov; 66(11): 3140-50.
• 2014
  Ruzehaji N, Kopecki Z, Melville E, Appleby SL, Bonder CS, Arkell RM, Fitridge R, Cowin AJ, , Attenuation of flightless I improves wound healing and enhances angiogenesis in a murine model of type 1 diabetes., Diabetologia 2014 Feb; 57(2): 402-12.
• 2013
  McInnes W, Ruzehaji N, Wright N, Cowin AJ, Fitridge R, , Venous ulceration contaminated by multi-resistant organisms: larval therapy and debridement., J Wound Care 2013 10; 22(10 Suppl): S27-30.
• 2013
  Kopecki Z, Ruzehaji N, Turner C, Iwata H, Ludwig RJ, Zillikens D, Murrell DF, Cowin AJ, , Topically applied flightless I neutralizing antibodies improve healing of blistered skin in a murine model of epidermolysis bullosa acquisita., J Invest Dermatol 2013 Apr; 133(4): 1008-16.
• 2013
  Ruzehaji N, Mills SJ, Melville E, Arkell R, Fitridge R, Cowin AJ, , The influence of Flightless I on Toll-like-receptor-mediated inflammation in a murine model of diabetic wound healing., Biomed Res Int 2013 ; 2013(): 389792.
• 2012
  Cowin AJ, Lei N, Franken L, Ruzehaji N, Offenhäuser C, Kopecki Z, Murray RZ, , Lysosomal secretion of Flightless I upon injury has the potential to alter inflammation., Commun Integr Biol 2012 Nov; 5(6): 546-9.
• 2012
  Lei N, Franken L, Ruzehaji N, Offenhäuser C, Cowin AJ, Murray RZ, , Flightless, secreted through a late endosome/lysosome pathway, binds LPS and dampens cytokine secretion., J Cell Sci 2012 Sep; 125(Pt 18): 4288-96.
• 2012
  Ruzehaji N, Grose R, Krumbiegel D, Zola H, Dasari P, Wallace H, Stacey M, Fitridge R, Cowin AJ, , Cytoskeletal protein Flightless (Flii) is elevated in chronic and acute human wounds and wound fluid: neutralizing its activity in chronic but not acute wound fluid improves cellular proliferation., Eur J Dermatol ; 22(6): 740-50.
• 2009
  Adams DH, Ruzehaji N, Strudwick XL, Greenwood JE, Campbell HD, Arkell R, Cowin AJ, , Attenuation of Flightless I, an actin-remodelling protein, improves burn injury repair via modulation of transforming growth factor (TGF)-beta1 and TGF-beta3., Br J Dermatol 2009 Aug; 161(2): 326-36.